Publicaciones (310) Publicaciones de José Juan García Marín

2024

  1. Impact of alternative splicing on cholangiocarcinoma progression through metabolic rewiring-induced epigenetic events

    Journal of Hepatology

  2. Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition

    Biochemical Pharmacology

  3. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

  4. Relationship between cholestasis and altered progesterone metabolism in the placenta-maternal liver tandem

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 2

  5. Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Clinical Pharmacology and Therapeutics

  6. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide

    Biomedicine and Pharmacotherapy, Vol. 170

  7. Strategies to enhance the response of liver cancer to pharmacological treatments

    American journal of physiology. Cell physiology, Vol. 327, Núm. 1, pp. C11-C33

  8. Synthesis, Characterization, and Potential Usefulness in Liver Function Assessment of Novel Bile Acid Derivatives with Near-Infrared Fluorescence (NIRBAD)

    Bioconjugate Chemistry

  9. Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells

    Biomedicine and Pharmacotherapy, Vol. 174

2023

  1. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  2. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs

    Biomedicine and Pharmacotherapy, Vol. 168

  3. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  4. Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity

    Cells, Vol. 12, Núm. 8

  5. Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells

    Biomedicine and Pharmacotherapy, Vol. 165

  6. Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma

    Biochemical Pharmacology, Vol. 214

  7. Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy

    Cancers, Vol. 15, Núm. 12

  8. Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors

    Biochemical Pharmacology, Vol. 217

  9. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

  10. eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma

    International Journal of Molecular Sciences, Vol. 24, Núm. 3

2022

  1. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

    Hepatology, Vol. 76, Núm. 5, pp. 1259-1274